Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aslan Officially Announces $40 Million Taiwan IPO

publication date: Apr 26, 2017
Singapore's Aslan Pharma officially announced it will conduct an IPO on the Taiwan exchange in May with trading beginning in June. The company will offer 10% of its shares to raise an expected $40 million, a valuation of $400 million. Aslan has raised over $100 million in venture capital and recorded paid-in capital of $36.5 million. Its website lists three drug candidates in clinical trials (one each in Phase I, II and III), two more in preclinical development, and a sixth in discovery. Aslan focuses on immunotherapies and targeted agents for tumors that are prevalent in Asia. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here